key: cord-0966552-p8185frw authors: Lazar, Harold L. title: Commentary: Compliance with the aats guidelines will prevent sternal wound infections and minimize postoperative complications in cardiac surgery patients during the covid-19 pandemic date: 2020-04-13 journal: J Thorac Cardiovasc Surg DOI: 10.1016/j.jtcvs.2020.04.016 sha: 0efc49033bde3dd785476bf6622b497142f5e483 doc_id: 966552 cord_uid: p8185frw nan There are currently no society guidelines for screening patients with COVID-19 prior to cardiac surgery. In view of the fact that patients requiring surgery may be asymptomatic carriers of the virus, it is not unreasonable that ALL PATIENTS UNDERGOING CARDIAC SURGERY DURING THE COVID-19 PANDEMIC BE SCREENED FOR THE VIRUS. This will identify those patients who will require isolation perioperatively and those health care workers who must wear Personal Protective Equipment (PPE) in caring for these patients. If available, surgery should be performed in an OR with a negative pressure environment to reduce the dissemination of the virus to locations outside the OR (4). If a negative pressure room is not available, a higher frequency of air exchanges will help to more rapidly reduce the viral load within the OR. In addition, it will be important to report the profiles, surgical procedures, and outcomes of COVID-19 patients undergoing cardiac surgery to national databases, such as the STS, to better understand the risk for patients and health care workers. The AATS guidelines give a CLASS I recommendation that ALL DISTANT, EXTRATHORACIC INFECTIONS SHOULD BE TREATED PROR TO CARDIAC SURGICAL PROCEDURES. This should include all respiratory tract infections. While it may not be possible to delay surgery to achieve a full course of antibiotic therapy in COVID-19 patients until the infection has resolved, it important that cultures be obtained and the appropriate antibiotics instituted prior to surgery. Since the respiratory system is the most common site for severe COVID-19 infections, and in view of the fact that a significant number of patients will have underlying pulmonary disease and a history of smoking, sputum specimens should be obtained in addition to nasopharyngeal swabs to detect underlying pulmonary bacterial infections which could contribute to postop pulmonary insufficiency requiring prolonged ventilatory support. Since COVID-19 patients tend to be older, they may suffer from benign prostatic hypertrophy and preoperative urine cultures should also be obtained in addition to routine urine analyses. The AATS guidelines recommend ( (6) . Intranasal mupirocin initiated within 24 hours of surgery, continued for 5 days and in combination with chlorhexidine gluconate bathing has been shown to significantly decrease the incidence of deep sternal wound infections (DSWI) following cardiac surgery (7) . Since nasal mupirocin has no effect in patients who are not nasal staphylococcus carriers, it should only be used in those patients who have either a positive nasal culture or PCR assay. In those patients who require emergent surgery in which the results of a nasal culture is not available at In this edition of the Journal, Mayeur et al report that in view of the COVID-19 pandemic, they have decided to suspend all preoperative nasal swab screening for cardiac surgery patients and will consider these patients as staphylococcus carriers and treat them all with intranasal mupirocin (8) . This is being initiated to protect health care workers from being exposed to sputum containing the COVID-19 virus. THE EXISITNG LITERATURE WOULD NOT UNDERGOING CARDIAC SURGERY. MR to staph species is increasing throughout the world. In Canada, the proportion of MR increased from 1.6% in 1995-1999; to 7.0% in 2000-2004 (9) . When mupirocin was administered to all patients during an MRSA epidemic in the United States, the incidence of MR increased over a 3 year period from 2.7% to 65% (10). In Brazil, the "blanket" use of mupirocin to eradicate staph species in all high risk patients resulted in a 65% incidence of MR (11) . This was decreased to 15% over a 5 year period when only staph nasal carriers were treated. It was hypothesized that short-term intranasal mupirocin, used as part of a perioperative prophylactic regimen, might not be associated with the emergence of MR. However, several studies have showed that when mupirocin is indiscriminately used as prophylaxis prior to surgical procedures, the prevalence of MR is increased. Bathoorn etal looked at the effects of short-term mupirocin therapy (24 hours prior to surgery and twice daily for 5 days postop) given to all surgical patients over a 5 year period (12) . There was a significant increase of high level MR to coagulase negative staphylococcus from 8% to 22%. Furthermore, isolates with high level MR were less susceptible to ciproflaxcin, clindamycin, and erythromycin. The authors concluded that not only could the routine use of mupirocin for prophylaxis in all surgical patients result in increased MR, it could also diminish the effectiveness of perioperative antibiotics for organisms other than staph species. Hetem etal studied the effects of nasal mupirocin combined with chlorhexidine soap for 5 days as surgical prophylaxis given to all patients irrespective of their staph aureus carrier status (13) . High level MR was 21% in coag negative patients prior to mupirocin but increased to 43% after mupirocin therapy. MR was associated with resistance to oxacillin, aminoglycosides, clindamycin, ciprofloxacin, trimethoprim/sulfamethoxide and rifampicin. In a study from South Africa, Wasserman etal found that the indiscriminate use of mupirocin to decolonize all patients increased the incidence of high level MR to 23.3% and was associated with resistance to cloxacillin and fluroquinolones (14) . Rudresh etal found that when mupirocin was used to treat all patients; high level MR to staph aureus was 10.5% and was associated with resistance to penicillin, erythromycin, ciprofloxin, clindamycin, and amoxicillin (15) . They concluded that the use of mupirocin should be based on nasal cultures and that the widespread use of mupirocin should be avoided. The indiscriminate use of mupirocin prophylaxis in cardiac surgery will increase the emergence of MR and limit its beneficial effects in reducing DSWI. It will lead to the emergence of more It is anticipated that COVID-19 patients will require longer periods of ICU, ventilator, inotropic and mechanical support as well as the need for renal replacement therapy. Van den Bergh etal have shown that this group of patients will benefit from more stringent glycemic control (serum glucose < 150 mg/dl) and that this will result not only in decreased sternal wound infections; but a significant decrease in operative mortality (17) . Patients with COVID-19 may be more likely to be in the hospital for > 3days prior to their surgery and /or transferred to a tertiary hospital or an ICU. MRSA may be a special concern in these patients and adding Vancomycin to these patients is not unreasonable, especially in those patients who will require a valve prosthesis or a vascular graft. Patients undergoing cardiac surgery during the COVID-19 pandemic are more likely to require more extensive procedures requiring extended periods of cardiopulmonary bypass and surgeries lasting more than 4 hours. Intraoperative redosing of Cefazolin has been found to reduce infections by 16% in procedures lasting more than 4 hours and following 120 minutes of cardiopulmonary bypass (20, 21) . Topical antibiotics, such as Vancomycin paste, applied to the cut edges of the sternum upon opening and closing, have been found to dramatically reduce the incidence of all sternal wound infections (22) . In contrast, bone wax acts as a foreign body, prevents bone union, and has been found to be an independent risk factor for sternal dehiscence and wound infections (23) . It should not be used in patients undergoing a sternotomy, especially in those infected with the COVID-19 virus. A low serum albumin is one of the strongest predictors of postoperative morbidity and mortality following cardiac surgery. Patients with a preoperative serum albumin < 2.5 mg/dl have a significant increase in operative mortality and sternal wound infections (24) . Whenever possible, surgery should be delayed for 7-10 days to allow for implementation of nutritional support; preferably through the enteral route which avoids intravascular catheter infections and metabolic complications. However, patients undergoing cardiac surgery during the COVID-19 pandemic will require urgent and emergent procedures. Many of these patients may have already been in the hospital or in an ICU on ventilator support for days prior to surgery. Patients with an albumin < 2.5 mg/dl, those with weight loss > 10% of body weight with 6 months , and who have evidence of muscle wasting will benefit the most from early postoperative nutritional support (25) . These patients will more likely require prolonged ventilator support, so that enteral feedings should be initiated as soon as hemodynamic stability has been achieved. Cardiac surgery performed during the COVID-19 pandemic will force surgeons to operate in uncharted waters. Adherence to the AATS guidelines for prevention of wound infections in conjunction with the STS guidelines for perioperative glycemic control and the STS guidelines for antibiotic usage, will provide a pathway for surgeons to safely navigate a postoperative course to decrease postoperative infections, minimize complications, and improve survival. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Mediastinitis following Coronary Artery Bypass Graft Surgery: Pathogenesis, Clinical Presentation, Risks and Management Expert Consensus Review: Prevention and management of sternal wound infections What we can do when a COVID-19 patient needs an operation: operating room preparation and guidance Elimination of staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant staphylococcus aureus. Anti-microbe Agents Chemo Ther Preventing surgical site infections in nasal carriers of staphylococcus aureus Does nasal screening for staphylococcus aureus before surgery compromise healthcare professional safety in the COVID-19 era? Mupirocin-resistant, methicillin-resistant staphylococcus aureus strains in Canadian hospitals Development of mupirocin resistance staphylococcus aureus after widespread use of nasal mupirocin ointment Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital Emergence of high-level mupirocin resistance in coagulase-negative staphylococcus associated with increased short-term mupirocin use Acquisition of high-level mupirocin resistance of CoNS following nasal decolonization with mupirocin High prevalence of mupirocin resistance associated with resistance to other antimicrobial agents in Staphylococcus aureus isolated form patients in private health care Prevalence of mupirocin resistance among staphylococci, its clinical significance and relationship to clinical use STS Practice Guidelines: Blood glucose management during adult cardiac surgery Intensive insulin therapy in critically ill patients The Society of Thoracic Surgeons Practice Guidelines Series: Antibiotic Prophylaxis in Cardiac Surgery; Part I: Duration The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery Part II: Antibiotic Choice Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery Plasma cefazolin levels during cardiovascular surgery: effect of cardiopulmonary bypass and profound hypothermic arrest Topical vancomycin in combination with perioperative antibiotics and tight glycemic control helps to eliminate sternal wound infections Sternocutaneous fistulas after cardiac surgery: Incidence and late outcome during a ten year followup Impact of body mass index and albumin on morbidity and mortality after cardiac surgery Incidence and mortality of hypoalbuminemic hospitalized veteran patients